Dipexium announces plans to price initial public offering of stock

Oppenheimer and Feltl will be the joint bookrunning managers for deal

By Devika Patel

Knoxville, Tenn., Feb. 6 - Dipexium Pharmaceuticals, LLC will price its initial public offering of stock with a 30-day greenshoe, according to a Form S-1 filed Thursday with the Securities and Exchange Commission.

Oppenheimer & Co. and Feltl and Co. are the joint bookrunning managers.

Proceeds will be used to continue clinical testing and commercialization of Locilex and for working capital and other general corporate purposes.

The pharmaceutical company is based in New York. It intends to list its common stock on the Nasdaq under the symbol "DPRX."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.